Basic Information
Elmiron
Regulatory Information
EMEA/H/C/004246
Authorised
June 2, 2017
14
July 15, 2022
Company Information
Germany
Herterichstrasse 1-3 81479 Munich
bene-Arzneimittel GmbH
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Elmiron. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Elmiron. For practical information about using Elmiron, patients should read the package leaflet or contact their doctor or pharmacist.